Systemic use of fluoroquinolone in children

Korean Journal of Pediatrics

Volumn 56, Issue 5, 2013, Pages 196-201

  Choi, Soo Han ^a   Kim, Eun Young ^b   Kim, Yae Jean ^c  

^a Korea Electric Power Research Institute (KEPRI)   (South Korea)

^b Chung Ang University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adverse effects; Child; Fluoroquinolones; Joint diseases

Indexed keywords

CEFIXIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; ENOXACIN; FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ACUTE OTITIS MEDIA; ANTHRAX; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; BACTERIAL SINUSITIS; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DYSENTERY; EOSINOPHILIA; GAIT DISORDER; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HUMAN; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PHOTOSENSITIVITY DISORDER; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINUSITIS; SKIN ALLERGY; SPECTRUM; SYSTEMATIC REVIEW (TOPIC); TENDINITIS; URINARY TRACT INFECTION;

EID: 84878426252     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2013.56.5.196     Document Type: Review

References (40)

1. Karande SC, Kshirsagar NA. Adverse drug reaction monitoring of ciprofloxacin in pediatric practice. Indian Pediatr 1992;29:181-8.
2. Lietman PS. Fluoroquinolone toxicities. An update. Drugs 1995;49 Suppl 2:159-63.
3. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999;28:352-64.
4. Andriole VT. The quinolones: past, present, and future. Clin Infect Dis 2005;41 Suppl 2:S113-9.
5. Grady RW. Systemic quinolone antibiotics in children: a review of the use and safety. Expert Opin Drug Saf 2005;4:623-30.
6. Bonafede ME, Blumer JL. Role of newer broad-spectrum betalactam and fluoroquinolone antibiotics in children. Adv Pediatr Infect Dis 1996;12:71-108.
7. White NJ, Dung NM, Vinh H, Bethell D, Hien TT. Fluoroquinolone antibiotics in children with multidrug resistant typhoid. Lancet 1996;348:547.
8. Freifeld A, Pizzo P. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Pediatr Infect Dis J 1997;16:140-5.
9. Redmond AO. Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom. Pediatr Infect Dis J 1997;16:147-9.
10. Sáez-Llorens X, McCoig C, Feris JM, Vargas SL, Klugman KP, Hussey GD, et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002;21:14-22.
11. Sideri G, Kafetzis DA, Vouloumanou EK, Papadatos JH, Papadimitriou M, Falagas ME. Ciprofloxacin in critically ill children. Anaesth Intensive Care 2011;39:635-9.
12. Sung L, Manji A, Beyene J, Dupuis LL, Alexander S, Phillips R, et al. Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials. Pediatr Infect Dis J 2012; 31:431-5.
13. Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am 2005;19:617-28.
14. Chien S, Wells TG, Blumer JL, Kearns GL, Bradley JS, Bocchini JA Jr, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol 2005;45:153-60.
15. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 2006;118:1287-92.
16. Sabharwal V, Marchant CD. Fluoroquinolone use in children. Pediatr Infect Dis J 2006;25:257-8.
17. Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert Rev Anti Infect Ther 2006;4:853-60.
18. Bradley JS, Jackson MA; Committee on Infectious Diseases; American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics 2011;128:e1034-45.
19. Melhus A. Fluoroquinolones and tendon disorders. Expert Opin Drug Saf 2005;4:299-309.
20. Forsythe CT, Ernst ME. Do fluoroquinolones commonly cause arthropathy in children? CJEM 2007;9:459-62.
21. Sansone JM, Wilsman NJ, Leiferman EM, Conway J, Hutson P, Noonan KJ. The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop 2009;29:189-95.
22. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002;324:1306-7.
23. Chalumeau M, Tonnelier S, D'Athis P, Treluyer JM, Gendrel D, Breart G, et al. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics 2003;111(6 Pt 1):e714-9.
24. U.S. Food and Drug Administration. Drug approval package: cipro (ciprofloxacin hydrochloride) tablets, cipro IV (ciprofloxacin) solution, cipro (ciprofloxacin) oral suspension [internet]. Silver Spring: U.S. Food and Drug Administration; [cited 2012 Nov 25]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ nda/2004/019537s49_19847s27_19857s31_20780s13TOC.cfm.
25. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child 2011;96:874-80.
26. Kaguelidou F, Turner MA, Choonara I, Jacqz-Aigrain E. Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr Infect Dis J 2011;30:e29-37.
27. Chaudhari S, Suryawanshi P, Ambardekar S, Chinchwadkar M, Kinare A. Safety profile of ciprofloxacin used for neonatal septicemia. Indian Pediatr 2004;41:1246-51.
28. Dutta S, Chowdhary G, Kumar P, Mukhopadhay K, Narang A. Ciprofloxacin administration to very low birth weight babies has no effect on linear growth in infancy. J Trop Pediatr 2006;52:103-6.
29. Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007;26:879-91.
30. ClinicalTrials. gov. Moxifloxacin in pediatric subjects with complicated intra-abdominal infection (MOXIPEDIA) [Internet]. Bethesda: National Institutes of Health; [cited 2012 Nov 25]. Available from: http://clinicaltrials.gov/ct2/show/NCT01069900.
31. ClinicalTrials. gov. Safety, tolerability and pharmacokinetics of single dose intravenous moxifloxacin in pediatric patients [Internet]. Bethesda: National Institutes of Health; [cited 2012 Nov 25]. Available from: http://clinicaltrials.gov/ct2/show/ NCT01049022.
32. Kim SC, Park YC, Kim BG, Nam DH. Outpatient antibiotic prescription by pediatric and ENT physicians in Ulsan city. Korean J Clin Pharm 2010;20:145-50.
33. European Medicines Agency. 5-year report to the European Commision. General report on the experience acquired as a result of the application of the paediatric regulation [Internet]. London: European Medicines Agency; c2012 [cited 2012 Nov 25]. Available from: http://ec.europa.eu/health/files/paediatrics/2012-09_ pediatric_report-annex1-2_en.pdf.
34. European Medicines Agency. Ciprofloxacin Bayer-Article 30 referral-Annex I, II, II [Internet]. London: European Medicines Agency; c2012 [cited 2012 Nov 25]. Available from: http:// www.ema.europa.ed/docs/en_GB/document_library/Referrals_ document/Ciprofloxacin_Bayer_30/WC500008057.pdf.
35. World Health Organization. Pocket book of hospital care for children [Internet]. Geneva: World Health Organization; c2013 [cited 2012 Nov 25]. Available from: http://www.who.int/ maternal_child_adolescent/documents/9241546700/en/.
36. World Health Organization. The selection and use of essential medicines. Report of the WHO expert committee, 2011 [Internet]. Geneva: World Health Organization; c2013 [cited 2012 Nov 25]. Available from: http://apps.who.int/iris/bitstream/10665/44771/1/ WHO_TRS_965_eng.pdf.
37. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011;53:e25-76.
38. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72-e112.
39. World Health Organization. Guidelines for the programtic management of drug-resistant tuberculosis-2011 update [Internet]. Geneva: World Health Organization; c2013 [cited 2012 Nov 25]. Available from: http://apps.who.int/iris/bitstre am/10665/44597/1/9789241501583_eng.pdf.
40. Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr Infect Dis J 2007;26:865-7.